source
- Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M dealThe purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.BioPharma Dive · 27d ago↗ source
- STAT+: Pharmalittle: We’re reading about Anthropic drug development goals, Trump drug plan snags, and moreAnthropic announced the availability of Claude Science, which optimizes its large language model for use in scientific labs and by drugmakersSTAT · 27d ago↗ source
- STAT+: More signs that GLP-1s may help with peripheral artery diseaseAnthropic will begin developing drugs, BridgeBio pockets a billion, and more biotech news from The ReadoutSTAT · 27d ago↗ source